Supporting Manufacturing, Trade and Equitable Global Access to COVID-19 Vaccines

Equitable distribution was our North Star from day one. In order to ensure that every country that chooses the Pfizer-BioNTech COVID-19 vaccine can have access to it, two conditions had to be met: a price that all countries can afford and reliable manufacturing to enable broad global distribution.

To date (May 2023), Pfizer and BioNTech have shipped more than 4.6 billion vaccines to 181 countries and territories around the world, including:

- **55 countries / territories** in Europe
- **31 countries** in Asia/Pacific
- **17 countries / territories** in Middle East
- **45 countries** in Africa
- **33 countries** in the Americas

Pfizer and BioNTech have been committed to accelerating efforts to reach people all around the world since the start of the pandemic with an equitable access strategy focused on low-income and middle-income countries. As of May, 2023, we have delivered more than 1.8 billion doses to 112 low- and middle-income countries. As COVID-19 remains a global threat to health, we will continue to work closely with governments and partners all around the world to supply doses in alignment with demand through our agreements with governments and international partners. This sits alongside our work to provide expertise and resources for novel approaches that can bring help to strengthen healthcare systems where greater support may be needed.

Supply Pathways:
- Direct supply agreements to governments.
- Allocation via COVAX - both direct supply, and via U.S. / EU donation programs.
- As of April 30, 2023, we have delivered more than 632 million doses to 111 countries through the COVAX facility.
- Targeted humanitarian donation programs.

Pricing Policy:
- Pfizer adopted a tiered pricing policy during the pandemic and we remain committed to ensuring equitable access around the world.
- As we transition from a pandemic distribution model, we will maintain the agreed upon tiered pricing in those markets through to the end of those contracts.

Accord:
- Under Pfizer’s Accord for a Healthier World, we have committed to provide access to the vaccine, in addition to Pfizer’s full portfolio of medicines and vaccines, on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries.

With our industry partners, we also share the five priorities for future pandemic preparedness and response:
- **Sustain innovation ecosystems**
- **Build equitable access early on**
- **Foster sustainable global manufacturing**
- **Support an open trading environment**
- **Support greater country readiness**
Fundamental to our access strategy is work to globally scale up manufacturing.

From the outset, we have taken a relentless focus on efficiency to enable us to quickly scale up manufacturing. Reducing production timelines has been achieved by:

- Doubling our batch sizes to minimize time between batches and increasing the yield per batch.
- Expanding the supply of raw material from existing suppliers.
- Adding additional formulation rooms to increase formulation capacity by over 3x.
- Adding high-speed packing lines to increase the daily ship rate.
- Bringing on new suppliers.
- [Image showing the reduction from start to vial-ready production: Almost 50%]

We are also partnering to build up scale. The Pfizer-BioNTech global COVID-19 vaccine supply chain and manufacturing network now spans four continents and includes more than 20 facilities.

We select partners using a rigorous process based on several factors, including: quality, compliance safety track record, technical capability, capacity availability, highly trained workforce, project management abilities, and prior working relationship.

Steps involved in a tech transfer process for a new facility include: on-site development, equipment installation, engineering and process qualification tests, and regulatory approvals.

Together with our partner BioNTech, we will continue to explore and pursue opportunities to bring new partners into our supply chain network to further accelerate access to the COVID-19 vaccine.

Recommendations for policymakers:

- Harness the power of science. Manufacturers are engaged in unprecedented collaboration to support R&D and manufacturing, thanks in large part to intellectual property (IP) protections and other pro-innovation policies. R&D continues to be needed for special populations (e.g. children), tackling new variants, developing additional therapeutics, and preparing for future pandemics.

- Maintain a robust global network. The vaccine manufacturing process depends on a complex global network of suppliers, competing for raw materials and equipment. Trade bottlenecks, including export restrictions, regulatory barriers, tariffs, and customs red tape – add uncertainty, cost, and delay to both manufacturing and patient access.

- Strengthen Health Systems. Vaccine deployment requires scale up of ultra-cold chain capacity, trained health care personnel, and more resilient health system infrastructure to broadly support delivery, particularly in low and lower-middle income countries. In addition, issues with demand and vaccine confidence are faced in some countries.